Lowering risk of 25 G surgery

Article

Although 25 G sutureless vitrectomy has increased in popularity, it is associated with postoperative complications including hypotony, choroidal detachment, and endophthalmitis. Richard Kaiser, MD, from the Retina Service of Wills Eye Institute, Philadelphia, noted that the 25 G procedure has a 12.4 times greater risk of endophthalmitis when compared with the 20 G procedure.

Although 25 G sutureless vitrectomy has increased in popularity, it is associated with postoperative complications including hypotony, choroidal detachment, and endophthalmitis. Richard Kaiser, MD, from the Retina Service of Wills Eye Institute, Philadelphia, noted that the 25 G procedure has a 12.4 times greater risk of endophthalmitis when compared with the 20 G procedure.

In light of this, the Microsurgical Safety Task Force has disseminated guidelines aiming to reduce the high rate of endophthalmitis associated with 25 G vitrectomy. The measures suggested included: rinsing the lidocaine gel from the ocular surface to allow direct contact of povidone iodine 10% with the conjunctiva; displace the conjunctiva with a cotton tip rather than instruments such as forceps or a caliper, which may cause microholes; use angled, rather than straight-entry, incisions and a tapered exit, to facilitate wound closure and maintenance of preop IOP level; rather than filling the eye with fluid, conduct an air-fluid exchange; and maintain a low threshold for placing a suture at the end of the case.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.